RhumbLine Advisers’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $692K | Buy |
51,815
+7,146
| +16% | +$95.4K | ﹤0.01% | 2453 |
|
|
2025
Q1 | $455K | Buy |
44,669
+3,802
| +9% | +$38.7K | ﹤0.01% | 2637 |
|
|
2024
Q4 | $647K | Buy |
40,867
+391
| +1% | +$6.19K | ﹤0.01% | 2500 |
|
|
2024
Q3 | $2.35M | Sell |
40,476
-1,162
| -3% | -$67.5K | ﹤0.01% | 1816 |
|
|
2024
Q2 | $1.9M | Buy |
41,638
+7,111
| +21% | +$325K | ﹤0.01% | 1914 |
|
|
2024
Q1 | $2.29M | Buy |
34,527
+2,870
| +9% | +$190K | ﹤0.01% | 1839 |
|
|
2023
Q4 | $1.26M | Sell |
31,657
-886
| -3% | -$35.2K | ﹤0.01% | 2144 |
|
|
2023
Q3 | $1.04M | Sell |
32,543
-410
| -1% | -$13.1K | ﹤0.01% | 2188 |
|
|
2023
Q2 | $1.32M | Buy |
32,953
+4,862
| +17% | +$195K | ﹤0.01% | 2148 |
|
|
2023
Q1 | $1.2M | Buy |
28,091
+1,707
| +6% | +$72.9K | ﹤0.01% | 2044 |
|
|
2022
Q4 | $1.27M | Buy |
26,384
+3,027
| +13% | +$145K | ﹤0.01% | 2021 |
|
|
2022
Q3 | $879K | Buy |
23,357
+3,106
| +15% | +$117K | ﹤0.01% | 2204 |
|
|
2022
Q2 | $560K | Buy |
20,251
+4,365
| +27% | +$121K | ﹤0.01% | 2442 |
|
|
2022
Q1 | $864K | Buy |
15,886
+1,984
| +14% | +$108K | ﹤0.01% | 2189 |
|
|
2021
Q4 | $813K | Sell |
13,902
-283
| -2% | -$16.6K | ﹤0.01% | 2295 |
|
|
2021
Q3 | $561K | Buy |
14,185
+680
| +5% | +$26.9K | ﹤0.01% | 2494 |
|
|
2021
Q2 | $574K | Sell |
13,505
-170
| -1% | -$7.23K | ﹤0.01% | 2505 |
|
|
2021
Q1 | $842K | Buy |
13,675
+64
| +0.5% | +$3.94K | ﹤0.01% | 2267 |
|
|
2020
Q4 | $960K | Buy |
13,611
+6,588
| +94% | +$465K | ﹤0.01% | 2149 |
|
|
2020
Q3 | $271K | Sell |
7,023
-811
| -10% | -$31.3K | ﹤0.01% | 2560 |
|
|
2020
Q2 | $294K | Buy |
+7,834
| New | +$294K | ﹤0.01% | 2587 |
|